VentriFlo — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

VentriFlo is pioneering a return to physiologic, pulsatile blood flow for cardiopulmonary support with its True Pulse Pump system, which consists of a single-use consumable, a linear electromagnetic pump driver, and a control console. Founded in 2016 (with origins dating to 2000), the company is in the development stage, assembling a team with deep expertise in medical device engineering, perfusion, and commercialization. VentriFlo targets the large and established cardiopulmonary bypass and extracorporeal membrane oxygenation (ECMO) markets, positioning its technology as a paradigm shift that could become a new standard of care, though it faces significant regulatory and commercial hurdles.

Cardiovascular

Technology Platform

The True Pulse Pump system: a hardware platform using a linear electromagnetic motor to drive a flexible diaphragm in a single-use pump, generating a biomimetic, physiologic pulsatile blood waveform for cardiopulmonary support.

Opportunities

VentriFlo targets the large, established markets for cardiopulmonary bypass (CPB) and extracorporeal membrane oxygenation (ECMO), where a demonstrated clinical benefit from true pulsatile flow could command a premium price and drive adoption.

If successful, the technology could become a new standard of care in cardiac surgery and critical care, positioning the company for significant market share or an attractive acquisition.

Risk Factors

The company faces high clinical and regulatory risk, as it must prove superior safety and efficacy in pivotal trials for a Class III life-support device.

Commercialization risk is also significant, requiring disruption of entrenched continuous-flow pump standards and conservative hospital purchasing practices.

Financial risk is paramount, as the capital-intensive path to FDA approval demands substantial funding without current revenue.

Competitive Landscape

VentriFlo competes against dominant medical device giants like Medtronic, LivaNova, and Getinge, whose continuous-flow centrifugal pumps are the current standard of care for CPB and ECMO. Its competition is based on a paradigm shift (pulsatile vs. continuous flow) rather than incremental improvement, facing the challenge of displacing reliable, familiar technology with a new clinical value proposition.

More companies in Drug Delivery & Formulation →More companies in United States →